Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)

Trial Profile

Multicenter phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2019

At a glance

  • Drugs Amrubicin (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2018 Status changed from active, no longer recruiting to completed, as reported in an abstract presented at the 19th World Conference on Lung Cancer.
    • 26 Sep 2018 Primary endpoint has not been met. (Progression-free survival), as reported in an abstract presented at the 19th World Conference on Lung Cancer.
    • 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top